Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2023
April 2023, Vol 14, No 2
April 2023, Vol 14, No 2
New Subgroup Analysis Confirms Efficacy and Safety of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
By
Anne Rowe
ASCO GU 2023 HIGHLIGHTS
,
Prostate Cancer
,
Genitourinary Cancers
April 2023, Vol 14, No 2
An analysis from the ARASENS trial showed that the addition of darolutamide to androgen-deprivation therapy and docetaxel significantly improved overall survival in subgroups of patients with metastatic hormone-sensitive prostate cancer with high-volume and high-risk disease and should be considered the new standard of care for this patient population.
Read More
Cost-Effectiveness of GemCis with or without Durvalumab in Patients with Advanced Cholangiocarcinoma
Cholangiocarcinoma
April 2023, Vol 14, No 2
First-line standard of care for patients with advanced cholangiocarcinoma has evolved from a chemotherapy-only regimen with gemcitabine/cisplatin to include the immune checkpoint inhibitor durvalumab based on results from TOPAZ-1 showing that the addition of durvalumab improved progression-free survival and overall survival compared with GemCis alone.
Read More
Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions
Value-Based Care
April 2023, Vol 14, No 2
The results of a recent survey commissioned by AccessOne, which focused on healthcare affordability and the impact of rising costs of living, revealed that the majority (71%) of consumers feel that inflation is having a significant effect on their healthcare purchasing decisions or their ability to pay medical bills.
Read More
Zynyz Receives FDA Accelerated Approval for Merkel-Cell Carcinoma
FDA Approvals, News & Updates
,
Skin Cancer
April 2023, Vol 14, No 2
On
March 22, 2023
, the FDA granted accelerated approval to retifanlimab-dlwr (Zynyz; Incyte Corporation), a programmed cell death 1–blocking antibody, for the treatment of adult patients with metastatic or recurrent locally advanced Merkel-cell carcinoma.
Read More
Tafinlar plus Mekinist Combination Approved for Pediatric Low-Grade Glioma with BRAFᵛ⁶⁰⁰ᴱ Mutation
FDA Approvals, News & Updates
,
Head and Neck Cancer
April 2023, Vol 14, No 2
On
March 16, 2023
, the FDA approved dabrafenib (Tafinlar; Novartis) in combination with trametinib (Mekinist; Novartis) for the treatment of pediatric patients aged ≥1 year with low-grade glioma that harbors a
BRAF
V600E
mutation and who require systemic therapy.
Read More
FDA Expands Indication for Verzenio as Adjuvant Treatment for HR-Positive, HER2-Negative, Early Breast Cancer
FDA Approvals, News & Updates
,
Breast Cancer
April 2023, Vol 14, No 2
On
March 3, 2023
, the FDA approved abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive,
HER2
-negative, node-positive, early breast cancer at high risk for recurrence.
Read More
Jemperli Receives Regular FDA Approval for Advanced Endometrial Cancer
FDA Approvals, News & Updates
,
Gynecologic Cancer
,
Endometrial Cancer
April 2023, Vol 14, No 2
On
February 9, 2023
, the FDA approved dostarlimab-gxly (Jemperli; GlaxoSmithKline) for the treatment of adult patients with mismatch repair-deficient, recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or following a previous platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Read More
Trodelvy Now Approved for Pretreated Patients with HR-Positive, HER2-Negative Breast Cancer
FDA Approvals, News & Updates
,
Breast Cancer
April 2023, Vol 14, No 2
On
February 3, 2023
, the FDA approved sacituzumab govitecan-hziy (Trodelvy; Gilead Sciences/Immunomedics) for the treatment of patients with unresectable, locally advanced or metastatic hormone receptor (HR)-positive,
HER2
-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+ with a negative in situ hybridization test) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.
Read More
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
By
Phoebe Starr
Women's Health
,
Breast Cancer
April 2023, Vol 14, No 2
Young women with early-stage, hormone receptor-positive breast cancer attempting to become pregnant can safely pause endocrine therapy and resume it later, according to initial results from the international POSITIVE trial.
Read More
Addressing Health Equity in Bladder Cancer Care
By
Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS
,
Bladder Cancer
,
Genitourinary Cancers
April 2023, Vol 14, No 2
During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma